Tolerability and efficacy of combined antidepressant therapy;Eficacia y seguridad de la asociación de antidepresivos

Actas Espanolas de Psiquiatria

Volumn 30, Issue 2, 2002, Pages 75-84

  De la Gandara Martin J ^a   Aguera Ortiz L ^a   Ferre Navarrete, F ^a   Rojo Rodes E ^a   Ros Montalban S ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Antidepressant; Association; Augmentation; Combination; Efficacy; Tolerability

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DRUG COMBINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; MEDLINE; NEUROBIOLOGY; TREATMENT OUTCOME; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; ENGLISH ABSTRACT; HUMAN; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; HUMANS;

EID: 4243338105     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Tratamiento de la depresión resistente
2. New approaches to the treatment of refractory depression
3. Treatment choice after one antidepressant fails: A survey of northeaster psychiatrists
4. How often do the psychiatrics raise the dose when SSRIs do not work?
5. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current «next-step» practices
6. Pharmacology of antidepressants: Selectivity or multiplicity?
7. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine
8. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain
9. Redefining antidepressant efficacy toward long-term recovery
10. The long-term treatment of depression
11. The tolerability and efficacy of combined antidepressant therapy: Literature review
12. Combination treatment with antidepressants in refractory depression
13. Combined amitryptiline and phenerlzine poisoning
14. Combining tricyclic and monoamine oxidase inhibitor antidepressants
15. A review of combined tricyclic and MAOI therapy
16. A comparison of phenelzine and imipramine in depressed inpatients
17. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: A pilot study
18. A 3-year follow-up of a group of treatment-resistant depressed patients with aMAOI/tricyclic combination
19. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroup
20. The safety and efficacy of combined amitryptiline and tranylcipromine antidepressant treatment
21. Controlled and trial of trimipramine, monoamine oxidase inhibitors and combined tratment in depressed outpatients
22. Tricyclic antidepressants and monoamine oxidase inhibitors
23. A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment
24. Letter: Combined antidepressant medication
25. Concomitant isocarboxazid/mianserin treatment of major depressive disorder
26. Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression
27. Adverse consequences of fluoxetine-MAOI combination therapy
28. Combined SSRI-moclobemide treatment of psychiatric illness
29. An update of recent moclobemide interaction data
30. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses
31. Moclobemide and specific serotonin reuptake inhibitor combination treatment of resistant anxiety and depressive disorders
32. Interactions of moclobemide with concomitantly administered medication: Evidence from pharmacological and clinical studies
33. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression
34. Safety and tolerability of combined treatment with moclobemide and SSRIs: Asystematic study of 50 patients
35. Imipramine-desipramine association in depressive syndromes: EEG study during spontaneous sleep
36. The association of imipramine and desipramine in the treatment of depressions
37. Treatment for therapy-resistant depression
38. Rapid dowregulation of cerebral B-adrenoreceptors by combined treatment with imipramine and mianserine
39. Étude de la potentialisation de deux antidépresseurs entre eus
40. Combined treatment with imipramine and mianserin. A controlled pilot study
41. Post-stroke depression: Combined treatment with imipramine or desipramine and mianserin. A controlled clinical study
42. Mianserin added to tryciclic antidepressant in depressed patients nor responding to a tricyclic antidepressant alone. A randomized, placebo-controlled, double-blind study
43. Non-response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation
44. Interaction of fluoxetine with tricyclic antidepressants
45. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report
46. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
47. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression
48. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study
49. Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
50. Serious adverse effects of combining fluoxetine and tricyclic antidepressants
51. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis
52. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses
53. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression
54. Mirtazapine: Clinical overview
55. Mirtazapine augmentation in the treatment of refractory depression
56. Comparison of 2 treatment strategies for depressed in patients: Imipramine and lithium addition or mirtazapine and lithium addition
57. Hypomania associated with mirtazapine augmentation of sertraline
58. Hypertension during co-prescription of mirtazapine and low-dose amitryptiline
59. Treating antidepressant nonresponders with augmentation strategies: An overview
60. Augmentation strategies in depression 2000
61. Augmentation and combination strategies in treatment-resistant depression